Two-day dosing versus one-day dosing of azithromycin in children with severe trachoma in tanzania

John Campbell, Harran Mkocha, Beatriz Munoz, Sheila K. West

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: To determine whether 2-day dosing of azithromycin may improve the efficacy of azithromycin dosing in children with severe trachoma. Methods: Fifty children with severe trachoma (defined as either trachoma intense or follicular trachoma with ten or more follicles) were enrolled from five villages in Kongwa, Tanzania. Enrollment occurred within 1 month and within the same district as the historical control population of 99 children with severe trachoma, all of whom received 1-day dosing. Baseline data on age, sex, and trachoma status were obtained, and swabs for determination of Chlamydia trachomatis were taken. All 50 children received 20 mg/kg azithromycin daily for 2 days, which was directly observed. Children were followed up at 6 weeks for trachoma and infection. The laboratory was masked to treatment assignment. Results: Baseline characteristics were similar between the treatment group and the control group. A total of 1/46 (2.2%) of children in the treatment group were polymerase chain reaction (PCR)-positive at 6 weeks, a 96.3% reduction from baseline, compared to 13/96 (13.5%) in the historical control group, an 89.4% reduction. This difference was statistically significant. However when modeled using logistic regression and accounting for age, gender, weight, and baseline percent PCR positivity, the difference was not significant. Prevalence of clinical trachoma did not differ between the groups at 6 weeks. Conclusion: For children with severe trachoma, a randomized controlled trial of 2-day versus 1-day treatment may be warranted.

Original languageEnglish (US)
Pages (from-to)38-42
Number of pages5
JournalOphthalmic Epidemiology
Volume19
Issue number1
DOIs
StatePublished - Feb 2012
Externally publishedYes

Fingerprint

Trachoma
Azithromycin
Tanzania
Polymerase Chain Reaction
Control Groups
Chlamydia trachomatis
Therapeutics
Randomized Controlled Trials
Logistic Models
Weights and Measures

Keywords

  • Azithromycin
  • Clinical trial
  • Dosing
  • Tanzania
  • Trachoma

ASJC Scopus subject areas

  • Ophthalmology
  • Epidemiology

Cite this

Two-day dosing versus one-day dosing of azithromycin in children with severe trachoma in tanzania. / Campbell, John; Mkocha, Harran; Munoz, Beatriz; West, Sheila K.

In: Ophthalmic Epidemiology, Vol. 19, No. 1, 02.2012, p. 38-42.

Research output: Contribution to journalArticle

Campbell, John ; Mkocha, Harran ; Munoz, Beatriz ; West, Sheila K. / Two-day dosing versus one-day dosing of azithromycin in children with severe trachoma in tanzania. In: Ophthalmic Epidemiology. 2012 ; Vol. 19, No. 1. pp. 38-42.
@article{1dcf37a375af422bb1ab9cb8ebee3f1d,
title = "Two-day dosing versus one-day dosing of azithromycin in children with severe trachoma in tanzania",
abstract = "Purpose: To determine whether 2-day dosing of azithromycin may improve the efficacy of azithromycin dosing in children with severe trachoma. Methods: Fifty children with severe trachoma (defined as either trachoma intense or follicular trachoma with ten or more follicles) were enrolled from five villages in Kongwa, Tanzania. Enrollment occurred within 1 month and within the same district as the historical control population of 99 children with severe trachoma, all of whom received 1-day dosing. Baseline data on age, sex, and trachoma status were obtained, and swabs for determination of Chlamydia trachomatis were taken. All 50 children received 20 mg/kg azithromycin daily for 2 days, which was directly observed. Children were followed up at 6 weeks for trachoma and infection. The laboratory was masked to treatment assignment. Results: Baseline characteristics were similar between the treatment group and the control group. A total of 1/46 (2.2{\%}) of children in the treatment group were polymerase chain reaction (PCR)-positive at 6 weeks, a 96.3{\%} reduction from baseline, compared to 13/96 (13.5{\%}) in the historical control group, an 89.4{\%} reduction. This difference was statistically significant. However when modeled using logistic regression and accounting for age, gender, weight, and baseline percent PCR positivity, the difference was not significant. Prevalence of clinical trachoma did not differ between the groups at 6 weeks. Conclusion: For children with severe trachoma, a randomized controlled trial of 2-day versus 1-day treatment may be warranted.",
keywords = "Azithromycin, Clinical trial, Dosing, Tanzania, Trachoma",
author = "John Campbell and Harran Mkocha and Beatriz Munoz and West, {Sheila K.}",
year = "2012",
month = "2",
doi = "10.3109/09286586.2011.627490",
language = "English (US)",
volume = "19",
pages = "38--42",
journal = "Ophthalmic Epidemiology",
issn = "0928-6586",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Two-day dosing versus one-day dosing of azithromycin in children with severe trachoma in tanzania

AU - Campbell, John

AU - Mkocha, Harran

AU - Munoz, Beatriz

AU - West, Sheila K.

PY - 2012/2

Y1 - 2012/2

N2 - Purpose: To determine whether 2-day dosing of azithromycin may improve the efficacy of azithromycin dosing in children with severe trachoma. Methods: Fifty children with severe trachoma (defined as either trachoma intense or follicular trachoma with ten or more follicles) were enrolled from five villages in Kongwa, Tanzania. Enrollment occurred within 1 month and within the same district as the historical control population of 99 children with severe trachoma, all of whom received 1-day dosing. Baseline data on age, sex, and trachoma status were obtained, and swabs for determination of Chlamydia trachomatis were taken. All 50 children received 20 mg/kg azithromycin daily for 2 days, which was directly observed. Children were followed up at 6 weeks for trachoma and infection. The laboratory was masked to treatment assignment. Results: Baseline characteristics were similar between the treatment group and the control group. A total of 1/46 (2.2%) of children in the treatment group were polymerase chain reaction (PCR)-positive at 6 weeks, a 96.3% reduction from baseline, compared to 13/96 (13.5%) in the historical control group, an 89.4% reduction. This difference was statistically significant. However when modeled using logistic regression and accounting for age, gender, weight, and baseline percent PCR positivity, the difference was not significant. Prevalence of clinical trachoma did not differ between the groups at 6 weeks. Conclusion: For children with severe trachoma, a randomized controlled trial of 2-day versus 1-day treatment may be warranted.

AB - Purpose: To determine whether 2-day dosing of azithromycin may improve the efficacy of azithromycin dosing in children with severe trachoma. Methods: Fifty children with severe trachoma (defined as either trachoma intense or follicular trachoma with ten or more follicles) were enrolled from five villages in Kongwa, Tanzania. Enrollment occurred within 1 month and within the same district as the historical control population of 99 children with severe trachoma, all of whom received 1-day dosing. Baseline data on age, sex, and trachoma status were obtained, and swabs for determination of Chlamydia trachomatis were taken. All 50 children received 20 mg/kg azithromycin daily for 2 days, which was directly observed. Children were followed up at 6 weeks for trachoma and infection. The laboratory was masked to treatment assignment. Results: Baseline characteristics were similar between the treatment group and the control group. A total of 1/46 (2.2%) of children in the treatment group were polymerase chain reaction (PCR)-positive at 6 weeks, a 96.3% reduction from baseline, compared to 13/96 (13.5%) in the historical control group, an 89.4% reduction. This difference was statistically significant. However when modeled using logistic regression and accounting for age, gender, weight, and baseline percent PCR positivity, the difference was not significant. Prevalence of clinical trachoma did not differ between the groups at 6 weeks. Conclusion: For children with severe trachoma, a randomized controlled trial of 2-day versus 1-day treatment may be warranted.

KW - Azithromycin

KW - Clinical trial

KW - Dosing

KW - Tanzania

KW - Trachoma

UR - http://www.scopus.com/inward/record.url?scp=84856599634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856599634&partnerID=8YFLogxK

U2 - 10.3109/09286586.2011.627490

DO - 10.3109/09286586.2011.627490

M3 - Article

C2 - 22273357

AN - SCOPUS:84856599634

VL - 19

SP - 38

EP - 42

JO - Ophthalmic Epidemiology

JF - Ophthalmic Epidemiology

SN - 0928-6586

IS - 1

ER -